The company believes that it is the first to file an abbreviated new drug application containing a paragraph IV certification for FazaClo.
Cima Labs and Azur Pharma and Azur Pharma International have previously filed a suit in the US District Court of Delaware to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.